Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs.

Axcelead DDP generates drug candidates through its well-established drug discovery capabilities and innovative technologies, including AI. Leveraging its researchers' deep knowledge and extensive ...

Eli Lilly and Company ’s LLY stock has risen 21.1% in six months compared with an increase of 10.5% for the industry. The ...

An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 597.82% and ...

With a new investment in its two manufacturing sites in Ireland, Eli Lilly continues implementing the largest expansion ...

Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over ...

Jim Cramer warned that if the housing market rally keeps going, it might lead to a sell-off if the Federal Reserve announces ...

Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Eli Lilly with a target price of $1100 ...

Our Beagle Lilly Needs Help with Heart Surgery: For more information about Lilly health please visit <a href=" you would like to help us save Lilly's life you can donate through Paypal also <a href=" ...

Most trillion-dollar companies today are in the technology sector, but one particular healthcare stock is knocking on the ...

According to Benzinga Pro, Eli Lilly's peer group average for short interest as a percentage of float is 4.49%, which means ...